Jiangsu Hualv Biological Technology Co.Ltd. (300970) — Capital Reinvestment Ratio
Jiangsu Hualv Biological Technology Co.Ltd. (300970) has a Capital Reinvestment Ratio of 0.36x as of December 2025, meaning it reinvests 0% of its operating cash flow (CN¥345.31 Million) in capital expenditures (CN¥123.12 Million). See debt-free asset ratio of Jiangsu Hualv Biological Technology Co.L to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Jiangsu Hualv Biological Technology Co.Ltd. Capital Reinvestment Ratio (2019–2025)
This chart tracks Jiangsu Hualv Biological Technology Co.Ltd.'s Capital Reinvestment Ratio across 7 annual periods. Check Jiangsu Hualv Biological Technology Co.L total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Jiangsu Hualv Biological Technology Co.Ltd. (2019–2025)
Year-by-year Capital Reinvestment Ratio for Jiangsu Hualv Biological Technology Co.Ltd. from 2019 to 2025. For live market cap and broader valuation context, see market cap of Jiangsu Hualv Biological Technology Co.L.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.36x | CN¥345.31 Million | CN¥123.12 Million | ▼ -81.7% |
| 2024 | 1.95x | CN¥137.80 Million | CN¥268.22 Million | ▲ +44.7% |
| 2023 | 1.34x | CN¥166.67 Million | CN¥224.15 Million | ▼ -40.7% |
| 2022 | 2.27x | CN¥179.84 Million | CN¥407.91 Million | ▼ -7.7% |
| 2021 | 2.46x | CN¥83.08 Million | CN¥204.09 Million | ▲ +156.1% |
| 2020 | 0.96x | CN¥199.09 Million | CN¥190.96 Million | ▲ +108.3% |
| 2019 | 0.46x | CN¥213.96 Million | CN¥98.54 Million | — |